Literature DB >> 29955589

SUSTAINable management of type 2 diabetes: feasibility of use and safety of semaglutide.

Jun Shirakawa1, Yasuo Terauchi1.   

Abstract

Entities:  

Year:  2018        PMID： 29955589      PMCID： PMC6015953          DOI： 10.21037/atm.2018.01.35

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  27 in total

1.  Type 2 diabetes via β-cell dysfunction in east Asian people.

Authors:  Daisuke Yabe; Yutaka Seino
Journal:  Lancet Diabetes Endocrinol       Date:  2015-11-12       Impact factor: 32.069

2.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Authors:  Steven P Marso; Stephen C Bain; Agostino Consoli; Freddy G Eliaschewitz; Esteban Jódar; Lawrence A Leiter; Ildiko Lingvay; Julio Rosenstock; Jochen Seufert; Mark L Warren; Vincent Woo; Oluf Hansen; Anders G Holst; Jonas Pettersson; Tina Vilsbøll
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

Review 3.  Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005.

Authors:  J J Holst
Journal:  Diabetologia       Date:  2006-01-14       Impact factor: 10.122

4.  Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.

Authors:  Vanita R Aroda; Stephen C Bain; Bertrand Cariou; Milivoj Piletič; Ludger Rose; Mads Axelsen; Everton Rowe; J Hans DeVries
Journal:  Lancet Diabetes Endocrinol       Date:  2017-03-23       Impact factor: 32.069

5.  Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.

Authors:  Melanie Davies; Thomas R Pieber; Marie-Louise Hartoft-Nielsen; Oluf K H Hansen; Serge Jabbour; Julio Rosenstock
Journal:  JAMA       Date:  2017-10-17       Impact factor: 56.272

Review 6.  Novel factors modulating human β-cell proliferation.

Authors:  J Shirakawa; R N Kulkarni
Journal:  Diabetes Obes Metab       Date:  2016-09       Impact factor: 6.577

7.  Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.

Authors:  Jesper Lau; Paw Bloch; Lauge Schäffer; Ingrid Pettersson; Jane Spetzler; Jacob Kofoed; Kjeld Madsen; Lotte Bjerre Knudsen; James McGuire; Dorte Bjerre Steensgaard; Holger Martin Strauss; Dorte X Gram; Sanne Møller Knudsen; Flemming Seier Nielsen; Peter Thygesen; Steffen Reedtz-Runge; Thomas Kruse
Journal:  J Med Chem       Date:  2015-09-11       Impact factor: 7.446

8.  Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects.

Authors:  Helene Hausner; Julie Derving Karsbøl; Anders G Holst; Jacob B Jacobsen; Frank-Dietrich Wagner; Georg Golor; Thomas W Anderson
Journal:  Clin Pharmacokinet       Date:  2017-11       Impact factor: 6.447

9.  Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial.

Authors:  Christoph Kapitza; Kirsten Dahl; Jacob B Jacobsen; Mads B Axelsen; Anne Flint
Journal:  Diabetologia       Date:  2017-05-19       Impact factor: 10.122

10.  Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity.

Authors:  Julie B Hjerpsted; Anne Flint; Ashley Brooks; Mads B Axelsen; Trine Kvist; John Blundell
Journal:  Diabetes Obes Metab       Date:  2017-10-27       Impact factor: 6.577
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.